Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
1.72B | 1.39B | 1.14B | 773.91M | 370.25M | 560.62M | Gross Profit |
247.35M | 214.96M | 199.48M | 177.77M | 21.70M | 74.53M | EBIT |
84.76M | 84.61M | 104.27M | 98.18M | 6.09M | 34.41M | EBITDA |
138.79M | 123.69M | 112.08M | 100.66M | 206.28M | 48.85M | Net Income Common Stockholders |
62.46M | 60.72M | 45.17M | 68.92M | -23.75M | 14.12M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
296.31M | 296.31M | 293.59M | 286.51M | 261.17M | 219.80M | Total Assets |
933.36M | 933.36M | 966.21M | 867.36M | 817.49M | 728.71M | Total Debt |
321.01M | 321.01M | 229.36M | 200.98M | 260.56M | 256.55M | Net Debt |
27.21M | 27.21M | -58.66M | -32.11M | 67.08M | 153.29M | Total Liabilities |
522.59M | 522.59M | 407.67M | 356.72M | 372.34M | 367.65M | Stockholders Equity |
614.22M | 614.22M | 542.56M | 448.17M | 330.82M | 191.55M |
Cash Flow | Free Cash Flow | ||||
69.89M | 39.70M | 59.19M | 51.11M | 45.00M | 12.87M | Operating Cash Flow |
82.45M | 68.23M | 82.13M | 70.33M | 46.16M | 13.91M | Investing Cash Flow |
-170.37M | -65.52M | -7.11M | 16.54M | 95.49M | -180.84M | Financing Cash Flow |
162.28M | 3.42M | -20.09M | -47.75M | -51.70M | 163.30M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $1.39B | 33.17 | 6.50% | ― | 29.71% | 33.99% | |
77 Outperform | $18.03B | 15.42 | 27.07% | ― | 19.24% | 8.57% | |
76 Outperform | $81.93B | 17.77 | 6.07% | 4.10% | 4.02% | -43.51% | |
73 Outperform | $86.99B | 26.22 | 7.87% | 1.80% | 25.21% | -29.37% | |
67 Neutral | $30.20B | 25.06 | 7.40% | 1.41% | 10.70% | -49.85% | |
65 Neutral | $444.59B | 31.35 | 15.88% | 1.70% | 8.35% | -35.14% | |
49 Neutral | $6.84B | 0.05 | -53.14% | 2.48% | 24.49% | -3.26% |
Astrana Health, Inc. announced an update to its corporate presentation on January 14, 2025, which it plans to use at upcoming conferences and meetings. The company disclosed that on January 11, 2025, Prospect Medical Holdings, Inc. filed for bankruptcy, but the businesses and assets Astrana is acquiring are not affected by this filing, and the acquisition timeline remains unchanged.
Astrana Health, Inc. is set to showcase its financial insights at upcoming conferences, providing exciting opportunities for investors to delve into the company’s financial dynamics. The data shared is for informational purposes and not part of any formal financial filing, offering a transparent view without legal obligations.
Astrana Health, Inc. has granted special equity awards to key leadership members under its 2024 Equity Incentive Plan, aiming to retain talent and boost stockholder returns amid a competitive market. Executive Chairman Kenneth Sim, Vice Chairman Thomas Lam, CEO Brandon Sim, COO/CFO Chandan Basho, and Chief Medical Officer Dinesh Kumar are among those receiving performance and time-based restricted stock and units, ensuring alignment with company goals and rewarding performance.
Astrana Health, Inc. announced a significant acquisition of Prospect Health System’s businesses and assets for $745 million, aiming to enhance its healthcare delivery network across California, Texas, Arizona, and Rhode Island. The deal, expected to close in 2025, will expand Astrana’s provider network and improve access, quality, and value for its members. The acquisition is backed by a $1,095 million bridge loan commitment from Truist Bank and J.P. Morgan, underscoring Astrana’s strategic growth in the healthcare market.